These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effects of Dahuang Zhechong Pill on expressions of tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1 in rats with glomerulosclerosis].
    Author: Chen JH, Sun W, Zhou D, Gao K, He WM, Liu L.
    Journal: Zhong Xi Yi Jie He Xue Bao; 2008 May; 6(5):512-6. PubMed ID: 18471418.
    Abstract:
    OBJECTIVE: To explore the mechanisms of the beneficial effects of Dahuang Zhechong Pill (DHZCP), a Chinese patent herbal medicine, in treatment of chronic renal disease, and to investigate the effects of DHZCP on the expressions of renal tissue inhibitor of metalloproteinase-1 (TIMP-1) and plasminogen activator inhibitor-1 (PAI-1) mRNAs in rats with adriamycin-induced glomerulosclerosis. METHODS: Focal segmental glomerulosclerosis and diffuse mesangial proliferation were induced in rats by combined procedures, including unilateral nephrectomy, intravenous injection of adriamycin and giving high-fat foods. The rats were randomly divided into untreated group, benazepril-treated group and DHZCP-treated group. Another 6 rats were sham-operated as control group. After 12-week treatment, rats were sacrificed, reverse transcription polymerase chain reaction (RT-PCR) method and computerized image analytical technique were used to determine the expressions of TIMP-1 and PAI-1 mRNAs. RESULTS: Compared with the untreated group, the ratios of TIMP-1/beta-actin and PAI-1/beta-actin of the DHZCP-treated group were decreased, suggesting that DHZCP could down-regulate the expressions of TIMP-1 and PAI-1 mRNAs (P<0.05). Benazepril could significantly inhibit the expression of TIMP-1 mRNA compared with that of the untreated group (P<0.05) CONCLUSION: DHZCP can down-regulate the expressions of TIMP-1 and PAI-1 mRNAs in renal tissues of rats with focal segmental glomerulosclerosis and diffuse mesangial proliferation, which may be its action mechanism in treating chronic renal disease.
    [Abstract] [Full Text] [Related] [New Search]